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Abstract 
 In this thesis we will explore the topic of cytotoxic necrotizing factors (CNFs) and show 
the creation of chimeric constructs to further test the details of CNF translocation into the cell. 
The CNF family of toxins is under the larger family of dermonecrotic AB toxins. These AB 
toxins have the ability to cause dermonecrosis when applied to the skin of animals. Among the 
dermonecrotic toxins, Pasteurella multocida toxin (PMT) and cytotoxic necrotizing factors 1, 2, 
and Y (CNF1, 2, and Y) are of interest. PMT, CNF1, CNF2, and CNFY are closely related in 
amino acid sequence. In a previous study on PMT, the method of translocation of the toxin into 
the cell for the release of the active domain was studied. Results showed that PMT enters the cell 
through back-trafficking in the endosomal pathway. It was also found that CNFs follow this 
same pathway into the cell. Interestingly, CNF1 and CNF2 were found to behave with increased 
efficiency of translocation across the endosomes when subjected to low levels of the inhibitors 
bafilomycin A1 (BafA1) and ammonium chloride (NH4Cl) compared with CNFY and PMT. A 
sequence comparison showed that CNF1 and CNF2 have higher pI in a specific region on the 
translocation domain than that of CNFY and PMT; a probable cause of the difference in 
translocation under low inhibitor levels. This being so, an experiment to specifically isolate and 
test the differences in activity caused by the translocation region was proposed. Chimeric CNF 
constructs involving variable translocation domains among the CNFs with constant activity 
domain and vice versa are proposed. In this thesis we specifically discuss the construction of the 
CNFY1 chimera from CNFY translocation domain and CNF1 activity domain. Generation of 
this chimera provides a foundation for additional constructs, as well as direction to begin testing. 
Using serum response element (SRE) has been seen as an effective way to test cellular activity 
for PMT and CNFs. In this thesis, we focus on the construction of CNF chimeras so that SRE-
based reporter tests may be conducted in future studies.    
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Chapter 1: Introduction 
 
1.1 Bacterial Toxins 
Bacteria have found many different ways to increase virulence within hosts. 
Pathogenicity factors, such as antibiotic resistance, cell wall modification, and secreted 
exotoxins, increase survivability of the pathogen within the host. An exotoxin is a poisonous 
substance made and secreted by bacteria into its surrounding medium. They are usually produced 
inside the pathogen and are secreted outside the bacterial membrane through various secretion 
pathways and then bind to and affect the host target cells. Despite its detrimental effects, it is 
possible to use the toxin mechanisms for beneficial purposes. The transmembrane transport 
system is naturally used for mobilizing toxin catalytic domains, but it may be possible to use the 
same transport to carry other desired chemicals or proteins as cargo for delivery into cells. In 
making these chimeric proteins, hormones and other chemicals can have very specific targeting 
to cells through their receptor-binding domains.  It could also be possible to alter the binding and 
transmembrane portions of the toxin to modify the target cell or receptor specificity. This is very 
powerful in regulating downstream effects in a multisystem organism such as an animal or 
human. There has been a successful attempt to create a drug specifically targeting lymphoma 
cells that express CD25 using chimeric “fusion” proteins based on toxins [1]. This would be a 
possible route to explore after more depth of inquiry has been done on toxin targeting, 
translocation, and catalysis.  
 
1.2 Exotoxins 
There are three types of exotoxins that are classified by their method of application. Type 
I toxins are characterized by their ability to hyperactivate host defenses. Known as 
superantigens, these proteins stimulate inflammation in the host by profusely binding to T4 
lymphocytes and antigen-presenting cells, causing the abundant release of cytokines such as 
interleukin-2. Excess amounts of cytokines circulating in the blood stream cause endothelial 
damage, shock, intravascular coagulation, and organ failure. Type II toxins are characterized by 
the ability to form pores in the target membranes and/or damage the membrane. Pores are formed 
by some Type II toxins protein insertions into the target membrane, while other membrane-
damaging effects come from phospholipase toxins that degrade membrane molecules. Very often 
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they are necrotic in nature, leaving dead flesh in the affected area. Type III toxins are known as 
AB toxins. AB toxins have two parts to the protein. There is generally a binding and/or 
translocation domain (B part) and a catalytic domain (A part). Entry of the AB toxin into the host 
cell occurs first by binding of the B domain to a surface receptor of the host cell. This triggers 
one of two events depending on the nature of the toxin. Either the toxin-receptor complex is 
phagocytosed into the cell and the A domain released into the cytosol, or the A domain is 
directly translocated across the phospholipid bilayer by the B part. The exact mechanism for 
translocation across the membrane has not yet been elucidated and further studies are being 
conducted. If the toxin receptor complex is phagocytized, the vesicle then fuses with the 
endosome. From this point, there are a variety of methods that the A domain uses to escape into 
the cytosol. In one of these pathways, the endosome acidifies, causing the A domain to 
translocate across the membrane and be released into the cytosol. Other toxins such as ricin toxin 
(RT) and cholera toxin (CT) are trafficked through the Golgi into the ER where they enter the 
cytosol. Finally, toxins can also move into the cytosol from the recycling endosome as seen in 
Pseudomonas exotoxin (PE) [2, 3]. Once in the cytosol many A domains, such as with CT and 
CNF (cytotoxic necrotic factor), will enzymatically modify G-proteins causing them to be 
constitutively active.  
 
1.3 G-Proteins 
G-proteins are a major part of host cell signaling. Many of them are coupled with a G-
protein coupled receptor (GPCR) that resides on the cell membrane to receive extracellular 
signals. GPCRs are membrane bound proteins that serve as a signal relay from extracellular to 
intracellular signals. They are made up of seven transmembrane alpha helices linked to an 
extracellular receptor. The cytosolic side is bound to a G-protein. When a ligand binds to the 
receptor the GPCR changes conformation and acts as a guanine nucleotide exchange factor 
(GEF) for the G-protein [4]. G-proteins act as the start of a signaling pathway that activates 
downstream activities. G-proteins start with GDP bound to them. Upon stimulation by the GEF, 
the alpha subunit releases bound GDP and binds GTP. When activated by a substrate, the GDP is 
exchanged for a GTP to activate the G-protein, and then the G-protein binds to the target 
molecule to activate it. GTP is hydrolyzed back to GDP and the G-protein converts back to its 
inactive state. The activated target molecule then continues the signal cascade downstream.  
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G-proteins can be monomeric or heterotrimeric. Heterotrimeric G-proteins have alpha, 
beta, and gamma subunits. The alpha subunit is about 45-47 kDa, the beta subunit 35 kDa, and 
the gamma subunit 7-9 kDa. The alpha, beta, and gamma subunits are linked together and bound 
to the GPCR. This allows the beta-gamma complex to disassociate [5]. The beta-gamma 
complex activates different signaling cascades before returning to the alpha subunit. The alpha 
subunit is a GTPase that hydrolyzes GTP to GDP and rebinds to the beta-gamma subunit. 
Monomeric G-protein is formed from a single protein chain. There are many families and classes 
of monomeric G-proteins. Many of these G-proteins are themselves modified by other proteins. 
Due to the tight binding of GDP and slow hydrolysis of GTP on these small G-proteins, they are 
enzymatically augmented by other proteins [6]. GEF disassociates GDP from the protein and 
GTPase activating protein (GAP) facilitates hydrolysis of GTP to GDP. These two proteins are 
part of a cycle in activation and deactivation of monomeric G-proteins.  Monomeric G-proteins 
not only have the ability to interact with regulatory proteins, they also interact among 
themselves, switching processes on and off. Their size ranges from 20 to 40 kDa and their 
downstream effects are very diverse. Families such as Rho and Rac GTPases participate in 
regulation of the actin cytoskeleton. Other families such as SAPK and MEK regulate 
transcription and translation signaling in the cell [7].  
 
1.4 Toxins Affecting G-Protein Pathways 
Many toxins produced by pathogenic bacteria modify G-protein function during 
infection. Toxins that affect G-protein pathways usually do so by modifying certain regulatory 
proteins in this pathway, making them constitutively active or inactive. This has compounding 
effects because the signaling cascade is usually amplified as it proceeds downstream. 
Constitutive activity easily perturbs homeostasis. For example, toxins that activate Gαs cause 
activation of acetylate cyclase, which in turn produces cAMP. This causes a large outflow of 
ions and water from the cell, which in intestines results in diarrhea. CNF1 modifies RhoA 
GTPase by deamidating the glutamine in the active site at position 63, causing it to be 
constitutively active and stimulate actin polymerization [8]. Actin is a monomeric protein 
molecule that polymerizes in a double helix to form fibers. The fibers associate with each other 
to form actin bundles or actin networks. Bundles are formed by parallel running fibers while 
networks are fibers that run orthogonal to each other. Under normal situations the fibers provide 
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a stable structure and allows for movement of the cell surface. Constitutively active RhoA will 
cause rapid formation of actin stress fibers and change the shape of the cell. CNF2 also performs 
similar actions on RhoA; however, the targeted cells differ slightly from CNF1 toxins [9]. 
(Figure 1.1) 
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Figure 1.1  
 
 
 
 
 
 
 
  
Toxins act on the G-protein signaling cascade: This simplified diagram shows toxin 
action on G-protein pathways and the downstream signals. Cytoskeletal rearrangement 
can be achieved through a variety of different paths, either through PKC activation or 
RhoA activation. PMT locks Gα in the active conformation to increase downstream 
signaling. CNF family toxins lock RhoA in the active formation to increase downstream 
signaling.  
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1.5 Looking at Membrane Translocation 
The translocation of the active domain across the membrane into the cytosol of the host is 
only partly understood. Studies have been made to see where along the endosomal pathway 
translocation occurs. While the timing and conditions of translocation are better known, the exact 
molecular mechanism is still being studied. One pathway involves uptake and trafficking to the 
Golgi apparatus and subsequent translocation. The pathway starts with toxin binding to receptors 
at the host membrane followed by endocytosis. Some toxins such as PMT will bind to the 
membrane itself for cell uptake [10]. Toxins such as CNF1 and CNF2 bind to the laminin 
receptor precursor (LRP) for endocytosis [11].Endocytosis can be either clathrin-dependent or 
clathrin-independent. Vacuoles all converge at the endosome following endocytosis. From the 
endosome, some toxins are trafficked to the trans-Golgi network (TGN). From the TGN, some 
toxins are further trafficked to the ER membrane where they use the native protein channels to 
access the cytosol [12]. Ricin toxin uses this method to achieve entry into the cytosol. Ricin is a 
naturally occurring AB toxin found in the seed of the castor oil plant Ricinus communis [3].  
The alternate pathway for toxin translocation into the cytosol from the endosome uses the 
acidification process of the endosome. Toxins that use this pathway bind to the native receptors 
on the host cell and are ingested via clathrin-mediated phagocytosis or clathrin-independent 
phagocytosis. Similar to before, the phagosome is fused with the endosome. Once merged, 
acidification of the endosome causes insertion of the translocation domain into the membrane, 
forming a pore that mediates transfer of the catalytic domain into the cytosol [13]. The A part of 
the toxin is then translocated across the membrane into the cytosol and released in the cytosol. 
Notable toxins that follow this pathway are diphtheria toxin and botulinum neurotoxins [14, 15]. 
PMT, and CNFs 1, 2, 3 and y also follow this pathway [16, 17, 18]. (Figure 1.2) 
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Figure 1.2  
 
 
 
 
 
  
Many toxins utilize the endosomal pathway for infection: The toxins are 
phagocytosed and incorporated into the early endosome. Here ricin toxin (RT) 
continues on through the trans-Golgi network and is trafficked into the ER where it is 
released into the cytoplasm. PMT and toxins from the CNF family traffic to the 
endosome and translocate the activity domains across the endosomal membrane upon 
acidification. 
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1.6 Pasteurella multocida Toxin (PMT) 
In a previous study, PMT (Pasteurella multocida toxin) translocation of the activity 
domain into the cell was studied [19]. PMT causes atrophic rhinitis in pigs and inflammation in 
humans. In most animals, the effects of Pasteurella multocida infection include but are not 
limited to hepatic necrosis, nasal and splenic atrophy, pneumonia symptoms and even death [20]. 
PMT uses the endosomal pathway for uptake into the cell. Host cell binding requires an 
abundance of sphingomyelin and possibly a protein co-receptor [10]. After endocytosis, PMT is 
trafficked to the late endosome and consequently translocates across the membrane as the pH is 
lowered [16]. PMT indirectly affects the RhoA pathway through deamidation of Gαq causing it to 
lose GTPase activity and become constitutively active [21] [22].  
 
1.7 Cytotoxic Necrotizing Factor 1 (CNF1) 
The CNF toxins are secreted toxins, or exotoxins, produced by pathogenic strains of 
Escherichia coli [23]. The CNF toxins, like PMT, are classified as Type III toxins. CNF 1 also 
causes disease in humans as a result of infection with uropathogenic E. coli [24]. CNF1 enters 
the cell through clathrin-independent endocytosis. As the endosome matures and the pH drops, 
the toxin inserts into the membrane and translocates across the membrane of the late endosome 
and consequently releases the catalytic domain into the cytosol [25] [17]. Inside the cytosol, the 
catalytic domain acts on a GTPase, a member of the Ras protein family: RhoA [26, 20]. 
Deamidation of residue 63 in Rho, converting glutamine into glutamic acid, causes constitutive 
activity [8] [27]. Since RhoA is involved in actin polymerization, activation causes 
rearrangement of the actin cytoskeleton in the infected cell [28]. The deamidation seems to be 
catalyzed by a Cys-His catalytic diad at the active site [29] [30].  
 
1.8 Cytotoxic Necrotizing Factor Y (CNFY) 
Work on CNFY has only recently been expanding. There is still much that we do not 
know about the toxin. CNFY is a Type III toxin produced by Yersinia pseudotuberculosis [31]. 
In terms of amino acid sequence, it is 61% identical to that of CNF1. CNFY also takes the same 
route as CNF1 into the cytosol, following the endosomal pathway and translocating across the 
late endosome as the compartment acidifies [18]. There is also some overlap in binding receptors 
between CNF1 and CNFY [18]. Once in the cytosol CNFY selectively targets RhoA, 
9 
 
deamidating the Gln63, similar to CNF1 [32]. The downstream effects result in multinucleation 
and formation of stress fibers [32]. 
 
1.9 Previous Inhibition Studies on PMT and CNF 
Toxin translocation and trafficking properties were compared among members of the 
CNF family, CNF1, 2, 3, and Y, as well as to PMT [19], as described a previous study of PMT 
[16]. The reasoning behind this is comes from the N-terminal sequence similarity between PMT 
and CNF1, which may point to a functional similarity (Figure 1.3). Using SRE-luciferase as a 
reporter assay, the intracellular activities of PMT, CNF1, 2, 3, and Y were compared. Testing 
included inhibition with varying concentrations of BafA1, cytochalasin D, nocodazole, 
LY294002, NH4Cl, and BFA. While the results were able to confirm the entry of PMT and CNF 
into the cytosol from the late endosome, there were also notable differences between the cellular 
response to PMT, CNFY, and CNF3 and that of CNF1 and CNF2. It has also been previously 
shown that protonation of specific residues in the translocation domain affect the translocation of 
the catalytic domain [25]. 
The findings indicated that CNF1 and CNF2 increased activity under low levels of 
inhibitor concentrations, specifically BafA1 and NH4Cl, while CNFY and PMT did not. 
However, at higher levels of inhibitor concentrations, activity was reduced for both PMT and all 
CNFs studied. This caused speculation as to whether this phenomenon was due to the differences 
in net charge in the N-terminus, which is presumably responsible for translocation, or the 
difference in the pI of this same region. The difference in pI for CNF1 and CNF2 is over 2 units 
higher than that of CNF3, CNFY and PMT in the region of residues 119-267 of CNF1 (and 
corresponding regions of CNF2, 3, Y and PMT). CNF1 and CNF2 have a net charge of 2 in this 
region while CNF3 and Y have a net charge of -4 and -3 for PMT [19].  
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Figure 1.3  
 
 
 
 
  
Protein Sequence Alignment Comparison of PMT and CNF1: Using FASTA for 
alignment, we find that PMT and CNF1 share high similarity on the N-terminus [37]. There is 
a 62.2% sequence similarity between residues 29-607 on PMT and residues 8-564 on CNF1. 
There is a 25.5% identity consensus on the compared sequence as well. These regions fall 
within the N-terminus of the proteins, which acts as binding and translocation function for 
toxin entry.  
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This being so, it is possible that chimeric CNFs with mutations in those specific 
translocation domain residues would also affect translocation. A practical way to test this would 
be to use different translocation domains from closely related CNF toxins while retaining the 
original activity domain. Due to knowledge of previous data on the activity of CNF1, 2, and Y, it 
follows to use these toxins as a basis for these experiments. Translocation regions in CNF1 and 
CNF2 are similar to each other but dissimilar to that of CNFY. Switching the translocation 
domain of CNFY with that from CNF1 and CNF2 allows us to determine if the translocation 
domain is responsible for the observed differences in activities and to possibly isolate differences 
to a specific region. 
 
1.10 Construction of Chimeric Proteins 
Hypothesis 
 To further explore this hypothesis, we generated a series of chimeric CNFs and 
performed comparative analyses on them as previously described [19, 16]. Using SRE-luciferase 
reporter assay as an indicator for activity, we wanted to test these chimeric proteins under 
varying concentrations of inhibitors to see if the increase in activity can be localized to a 
responsible domain.  
In this study, I aim to start construction and isolation of the chimeric CNFs so that further 
testing can be done on them. We will make a chimeric protein by swapping the catalytic C-
terminal of CNFY with that of other CNFs, while keeping the receptor binding and 
transmembrane domain constant (Figure 1.4). CNFY N-terminal with CNF1 C-terminal protein 
would be labeled CNFY1. Thus, the different constructs that I would be comparing are: CNFY, 
CNF1, and CNFY1. Running this chimera against the wild type CNFY and CNF1 under different 
levels of inhibitor, we will be able to determine a number of things. First, if CNF1 N-terminal is 
changed to CNFY, a change of activity may mean that the difference between CNF1 and CNFY 
activity is caused by translocation efficiency. This allows us to narrow down the differences in 
translocation activity to the N-terminal (and the role of residues 199-267 in the translocation 
process). Second, with CNFY C-terminal is changed to that of CNF1, we want to see if any 
change in activity for CNFY1 could be attributed to the catalytic domain. 
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Figure 1.4 
  
Construction of CNFY-Y and chimeric swap: CNFY gene in the original plasmid is taken 
and the NheI site is removed. This becomes the CNFY-∆NheI construct. From this construct, 
a new 2 kbp fragment is created via PCR and reintroduced into the plasmid, making an 
intermediate construct that now contains BamHI, NheI, and KpnI. The C-terminus is created 
from CNFY-∆NheI via PCR and ligated into the intermediate construct between NheI and 
KpnI to create CNFY-Y. CNFY-Y is used as a template for other chimeric constructs. To 
create CNFY1, the C-terminal PCR fragment from CNF1 replaces the fragment between 
NheI and KpnI on CNFY-Y. 
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Chapter 2: Methods 
 
2.1 Bacterial Strains, Cloning, and Mutagenesis 
Plasmid constructs 
DNA for cnf1, and cnfy was generated via PCR from their original plasmids. pQE-CNF1 
was obtained from Dr. Alison O’Brian at Uniformed Services University and pQE-CNFY was by 
Tana Repella of Wilson Lab from genomic DNA isolated from Y. pseudotuberculosis strain YPIII 
[19]. pQE-CNFY was first treated with NheI, blunt-ended with Mung bean nuclease and religated 
with T4-DNA ligase. This ∆-NheI-pQE-CNFY was then used for introduction of a new NheI site 
between N-terminal 2 kbp and c-terminal 1 kbp fragment to generate pQE-CNFY-Y (Mengfei Ho 
and Stephanie Tham)(Figure 1.3). With this new NheI site and the N-terminal BamHI site, C-
terminal KpnI site, pQE-CNFY-Y was used to generate chimera CNFY1. A list of all the primers 
used is shown. (Table 2.1) 
 
cnfy1 
CNF1-C terminal was cloned out from a primer added NheI site to the KpnI site on the 
pQE-CNF1 plasmid. CNFY-N terminal was cloned out from the BamHI site to a primer added 
NheI site on pQE-CNFY. CNFY-N and CNF1-C are ligated together at the NheI site and ligated 
into the pQE vector from the BamHI site to the KpnI site resulting in the final vector (Figure 
2.1). 
 
superG-cnfy1 
The cnfy1 construct was PCR cloned from the BamHI to the KpnI site. Primer 
mutagenesis converted the N-terminal BamHI to a KpnI site and the C-terminal KpnI site to a 
NotI site. This fragment was ligated into the superG vector replacing the GFP gene. The superG 
vector is an engineered pGEpi-GFP vector for high expression of protein with a His tag, a 
thrombin-cleavage site and a KpnI site in front of GFP and a Not I site at it end (Mengfei Ho). 
The pGEpi vector was previously used and is itself a modified version of the pTrcHisC vector 
with a GFP tag added from the pGFPuv vector [33] (Figure 2.2). The construct was transformed 
into TOP10 cells for expression. 
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Table 2.1 Primer list:  
PCR primers were used to generate PCR fragments of the different N and C-terminals from the 
plasmids.  
 
ST1 TCACCATCACCATCACCATCACGGATCCATG 
ST2 GAAGAGGTACCGTCTGTCCACAACTGCTAGCACTTCTACAGGTGCTTCATC 
ST3 GATGAAGCACCTGTAGAAGTGCTAGCAGTTGTGGACAGACGGTTT 
ST4 GACCCGGGGTACCACGGC 
ST9 GTAGAAGTGCTAGCAGTTGTGGACAG 
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Figure 2.1 
 
 
  
CNFY1 in pQE vector plasmid map: The CNFY1 plasmid is a chimeric DNA construct 
from pQE-CNFY, pQE-CNF1, and pQE-CNFY-Y. There is a PCR introduced NheI site 
between the catalytic domain and the binding and translocation domain. This construct was 
used to produce to produce the superG-CNFY1 plasmid as well as the CNFY1 protein. 
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Figure 2.2 
 
 
 
  
CNFY1 in superG vector plasmid map: The CNFY1 insertion PCR modified to start with 
KpnI replacing BamHI and ending with NotI replacing KpnI. This new insert was ligated into 
the superG vector. This vector was then transformed into TOP10 cells for expression.  
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DNA Amplification 
All DNA constructs in their respective vectors were then transformed into Escherichia 
coli TOP10 cell cultures. TOP10 cells were prepared using the Inoue method for competent cells 
[34]. Cells were grown in LB medium overnight at 37 oC and stored in 25% glycerol at -80 oC. 
 
2.2 Protein Expression 
CNFY1 
Starting from glycerol stock cultures, a Luria agar plate with 100 ug/mL ampicillin was 
streaked. The plates were grown overnight at 37 oC and single colonies are picked and used to 
inoculate 5 mL Luria broth tubes with 100 ug/mL ampicillin. Tubes were grown overnight at 37 
oC. 1 mL of each tube culture was taken and put into flasks 500 mL Luria broth with 100 ug/mL 
ampicillin, 8 flasks in total. Flasks were incubated at 37 oC until optical density of 0.8-1.0 at the 
600 nm wavelength. The flasks were induced with 10 ug/mL of isopropyl-beta-D-
thiogalactopyranoside (IPTG). Flasks were then incubated at room temperature (25 oC) 
overnight. Cells were harvested and spun down at 6000 rpm at 4 oC. Supernatant was discarded 
and the cells were resuspended in 200 mL Lysis buffer (1x PBS, a few drops of Igepal CA-630, 
200 mg benzamidine, 60 mg lysozyme, 60 mg PMSF, protease inhibitor (Sigma-Aldrich P8849), 
DNase (Sigma-Aldrich D5025), and RNase (Sigma-Aldrich R6513)) and sonicated to lyse 
contents. The suspension was centrifuged at 13,500 rpm for 2 hours at 4 oC. The supernatant was 
taken and run through a HIS-Select® HF Nickel Affinity Gel (Sigma-Aldrich) under pH 7.5 Tris 
buffer and eluted into a HiTrap Q HP column (GE Life Sciences) under pH 7.5 Tris buffer with 
100 mM imidazole. The column, with the protein bound, was then equilibrated with Tris buffer 
to pH 6.5 and eluted out with a increasing salt gradient of 1 M sodium chloride in pH 6.5 Tris 
buffer with 10 mL fractions caught at 0.1, 0.2, 0.22, 0.25, 0.3, 0.33, 0.35, 0.37, 0.50, and 1 M. 5 
µL of each fraction was run on an 8% SDS-PAGE gel. Gels were stained with Coomassie Blue 
for visualization (Figure 3.4). 
 
superG-CNFY1 
Procedures are similar to CNFY1 purification except the 1M NaCl gradient used was 0.1, 
0.2, 0.25, 0.33, 0.35, 0.4, 0.5, and 1 M. 5 µL of each fraction was run on an 8% SDS-PAGE gel. 
Gels were stained with Coomassie Blue for visualization (Figure 3.5).  
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CNFY 
Cell culture is from unmodified CNFY in pQE plasmid. Procedures are similar to CNFY1 
purification except the 1 M NaCl gradient used was 0.1, 0.2, 0.2, 0.2, 0.22, 0.25, 0.3, 0.35, 0.5, 
and 1 M. 5 µL of each fraction was run on an 8% SDS-PAGE gel. Gels were stained with 
Coomassie Blue for visualization (Figure 3.1, 3.2).  
 
CNF1 
Cell culture is from unmodified CNF1 in pQE plasmid grown in XL1-Blue cells. Protein 
expression in XL1-Blue showed stronger expression than in TOP10. Procedures are similar to 
CNFY1 purification except the 1 M NaCl gradient used was 0.1, 0.15, 0.2, 0.2, 0.22, 0.25, 0.3, 
0.5, and 1.0 M. Samples (5 µL) of each fraction were run on an 8% SDS-PAGE gel. Gels were 
stained with Coomassie Blue for visualization (Figure 3.3).  
 
2.3 Protein Concentration 
Relevant fractions of the eluted protein were loaded onto a HIS-Select® HF Nickel 
Affinity Gel column at pH 7.5 and eluted into a HiTrap Q HP column with 100 mM imidazole at 
pH 7.5. The column was equilibrated with Tris buffer to pH 6.5 and the protein was eluted out 
with a 1 M NaCl in Tris buffer gradient at pH 6.5 in 1 mL fractions. The gradient increases 0.1 
M each step with 2 fractions collected at each step and finishing with 6 fractions of 1 M NaCl. A 
Bradford assay was done to determine fractions containing the target protein. Samples (1 µL) of 
relevant fractions were then run on an 8% SDS-PAGE gel and stained with Coomassie Blue for 
visualization (Figure 3.6-3.9). All proteins were then desalted using PD-10 Desalting Column 
(GE Healthcare) in phosphate buffered saline (PBS) with 10% glycerol and collected into 0.5 mL 
fractions. Proteins are stored at -80 oC in PBS with 10% glycerol. 
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Chapter 3: Results 
 
3.1 Purification of CNFY, CNF1, and CNFY1 
CNFY, CNF1, CNFY1, and superG-CNFY were successfully purified under the stated 
conditions (see Methods). Samples run on SDS-PAGE showed interesting results. There were 
consistently two major products resulting from the purification: a shorter version of CNFY1 and 
CNFY at around 100 kDa and a full-length version of each at the expected size of ~115 kDa. The 
smaller 100 kDa fragment also exhibited a yellow color, when eluting from the nickel agarose 
column. This fragment might have resulted from some form of nickel-chelation during the metal 
ion-chelation column chromatography step. This form eluted from the Q HP anion exchange 
column between 0.3 M and 0.35 M NaCl (Figure3.1). However, the expected protein length is 
114 kDa to 116 kDa for a full-length CNF protein. In the longer versions purified, the protein 
eluted at 0.2 M NaCl and is about 115 kDa in size (Figures 3.1-3.5).  
The proteins were concentrated from the purified samples containing relevant protein 
with a HiTrap Q HP column (See Methods). Some purification samples were combined with 
previous samples to give higher density protein after concentration. The long version of CNFY 
and superG-CNFY1 were concentrated from just one purified preparation. The short version of 
CNFY and CNF1 were concentrated from two previous preparations respectively. The shorter 
version of CNFY1 was not concentrated. (Figures 3.6-3.9) 
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Figure 3.1 
 
  
Purification of CNFY short version: The short version of CNFY eluted out from a Q HP 
ion exchange column at 0.25 M to 0.35 M of NaCl. The size was around 100 kDa which is 
smaller than the expected 115.8 kDa size. Out of each 10 mL fraction of eluent collected, an 
equivalent of 2 µL was loaded into each well. This gel was run on 10% SDS-PAGE. The 0.25 
M to 0.5 M fractions were taken for concentration. 
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Figure 3.2  
 
  
Purification of CNFY long version: The long version of CNFY is eluted out from a Q HP 
ion exchange column between 0.2 M and 0.25 M NaCl. The size is around the expected 115.8 
kDa. Out of each 10 mL fraction an equivalent of 2 µL was loaded into each well. This was 
run on an 8% SDS-PAGE gel. The first two 0.2 M fractions were taken for concentration.  
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Figure 3.3  
 
  
Purification of CNF1: CNF1 was eluted out from a Q HP ion exchange column at 0.2 M 
NaCl. The size is around the expected 115.2 kDa. Out of each 10 mL fraction an equivalent of 
2 µL was loaded into each well. This was run on an 8% SDS-PAGE. The two 0.2 M fractions 
were taken for concentration.  
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Figure 3.4  
 
  
Purification of CNFY1 short version: The short version of CNFY1 eluted out from a Q HP 
ion exchange column between 0.3 M and 0.35 M NaCl. This protein is around 100 kDa, 
which is shorter than the expected 116.2 kDa. Out of each 10 mL fraction, an equivalent of 2 
µL was loaded into each well. This was run on a 10% SDS-PAGE gel. 
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Figure 3.5 
 
  
Purification of CNFY1 long version: superG-CNFY1 yielded the long version of the 
CNFY1 protein and eluted out from a Q HP ion exchange column between 0.2 M and 0.35 M 
NaCl. The extension into the later fractions was probably caused by the large quantity of 
proteins to elute out. The proteins are around the expected 116.2 kDa. An equivalent of 2 µL 
from each 10 mL fraction was loaded into each well. This was run on an 8% SDS-PAGE gel. 
The 0.2 M and 0.25 M fractions were taken for concentration.  
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Figure 3.6  
 
  
  
Concentration of CNFY short version: The short version of CNFY is concentrated down 
into 1 mL fractions using an increasing NaCl gradient on a Q HP ion exchange column. An 
equivalent of 1 µL from each fraction is loaded into each well. This is run on an 8% SDS-
PAGE gel and once again confirms the 100 kDa size.  
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Figure 3.7  
 
  
Concentration of CNFY long version: The long version of CNFY is concentrated into 1 mL 
fractions using an increasing NaCl gradient on a Q HP ion exchange column. An equivalent 
of 1 µL from each fraction is loaded into each well. This was run on an 8% SDS-PAGE gel.  
27 
 
Figure 3.8  
 
  
Concentration of CNF1: CNF1 is concentrated down into 1 mL fractions using an 
increasing NaCl gradient on a Q HP ion exchange column. An equivalent of 1 µL from each 
fraction is loaded into each well. This is run on an 8% SDS-PAGE gel.  
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Figure 3.9  
 
 
 
 
 
  
Concentration of CNFY1 long version: superG-CNFY1 was concentrated down into 1 mL 
fractions using an increasing NaCl gradient on a Q HP ion exchange column. An equivalent 
of 2 µL from each fraction was loaded into each well. This was run on an 8% SDS-PAGE gel.  
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Chapter 4: Discussion 
 
4.1 Production Efficiencies 
During protein production, there appeared two different variables that contributed to 
production efficiency. In TOP10 cells, protein production was significantly diminished. CNF1 
was optimally purified from XL1-Blue cells. This is in agreement with previous studies showing 
that CNF1 and CNF2 produced well in XL1-Blue cells [19]. The identity of the expression 
vector also has profound effects on the efficiency of protein production. The engineered superG 
vector seems to have amplified production many times over the original pQE vector. In 
comparing the short version of CNFY1 from a pQE vector and the long version from the superG 
vector, there is a dramatic difference in production (five-fold estimate). The superG vector has 
been engineered to have protein production capabilities without need for induction [33]. Current 
studies are to move all constructs into superG vectors for two reasons: to increase volume of 
protein production and to reduce degradation of product that was seen in CNFY1 protein 
purification. It is possible that this vector could be effective for other protein constructs as well.  
 
4.2 Differential Fragments 
During cultivation and purification of proteins, there were two distinct sizes of proteins 
that were eluted out. For both CNFY1 and CNFY, two consistent products were seen at a size of 
about 100 kDa and at the expected size of about 115 kDa. Each of the products was consistent in 
elution activity at certain pH as well. The larger 115 kDa product consistently eluted in earlier 
fractions than the smaller 100 kDa product. Consistent appearance indicates that the fragment is 
probable to have been generated during protein production in the bacteria. It is likely that the 
smaller fragment is derived from the larger one due to the fact that they both appear together 
during protein purification: one as a major product and one as a minor product. Both also have a 
His-tag so it is likely that amino acids lost from the C-terminal of the longer version produce the 
more acidic shorter version. During elution from a HiTrap Q HP column using a salt gradient, 
higher charged proteins, more acidic in this column, elute out later.  
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If we look at the CNFY1 protein sequence, it is 116 kDa, 1027 residues, and has a pI of 
5.11. If the C-terminus of the protein is cleaved to 98.6 kDa and 866 residues, the pI becomes 
5.04. If the entire C-terminus is cleaved, the pI becomes 4.84, but the size is reduced to 80 kDa 
and 704 residues. However, a shorter CNFY does not produce a significant change in the pI of 
the protein unless the entire C-terminus is cleaved (Table 4.1). The experimental data showed 
that the shorter fragment is more acidic as it elutes out at higher salt concentrations. We would 
need to see a decrease in protein pI in conjunction with the loss of amino acids to support this.  
One other way to test for the unknown fragment would be to run both fragments on an 
SRE-luciferase assay and assess activity. The prediction is that the shorter fragment should show 
little to no activity if it is missing the C-terminal catalytic domain. A CNF toxin missing the 
activity domain would be useful as a control for the activity domain.  
 
4.3 Other Constructs 
 With CNFY1 created, it is now possible to generate other constructs. Expanding beyond 
CNFY and CNF1, we can also look at CNF2. The pI of CNF1 differs from that of CNFY within 
the 119-267 equivalent region on CNF1 by over 3 pH units (7.65 and 4.67 respectively). 
However, a few residues are not conserved between CNF1 and CNF2 (Figure 4.1). In contrast, 
CNF1 and CNF2 differ in this critical region by about 0.3 pH units (7.65 and 7.91 respectively). 
Elucidating the repercussions of this difference could help us narrow down the responsible 
residues for the differential behavior among CNF1, CNF2 and CNFY. Creating other chimera 
constructs would give us more information in this direction. This being so, we have started work 
on constructing chimeric proteins between CNF1 and Y, and CNF2 and Y, switching both the N-
terminal and C-terminal domains (Figure 4.2).  
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Table 4.1 Comparison of pI values within the N-terminal domains of CNFY1 and CNFY:  
CNFY1 shows a steady decrease in pI as C-terminal residues are removed, this supports the data 
indicating that the 100 kDa product is the shorter, more acidic version of the longer one. CNFY 
does not show this trend until the entire C-terminal domain is cleaved, at which point, the amino 
acid sequence is identical with that of CNFY1. 
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Figure 4.1  
 
 
  
Sequence alignment comparison of CNF1, CNF2, and CNFY: CNFY, CNF1, and CNF2 
are compared on their residues from the 119-267 amino acid residues on CNF1 and 
corresponding residues on CNF2 and CNFY. ClustalW was used to align sequences [35] 
[36]. An asterisk (*) denotes a single, fully conserved residue, a colon (:) denotes a residue 
with strongly conserved properties, a period (.) denotes a residue with weakly conserved 
properties, and a blank ( ) denotes no conservation. Red denotes a small, hydrophobic, or 
aromatic residue (AVFPMILW), blue denotes an acidic residue (DE), magenta denotes a 
basic residue (RK), and green denotes a residue with a hydroxyl, sulfhydryl, or amine group 
(STYGCNGQ). 
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Figure 4.2  
 
  
Possible CNF chimeric constructs: All the chimera constructs of interest are listed here, 
including the ones created in this thesis. Congruent N and C-terminal constructs signify the 
wild-type version of the toxin. By exchanging both N and C-terminals we will be able to run 
detailed analysis on the effects of each domain in regards to SRE-luciferase activity.  
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4.4 Future Direction 
 This project has developed a reliable method of generating and purifying CNF toxins and 
chimeric constructs thereof. Our focus now is to finish construction of the possible chimeric 
permutations using CNF1, CNF2, and CNFY. Combining the N-terminal of CNF1 with the C-
terminal of CNFY is the immediate goal, as it will provide an additional piece of information 
regarding the differences between CNF1 and CNFY. Due to CNF2 being more similar to CNF1 
in residue sequence than CNFY, permutations of CNFY using CNF2 N and C-terminus is also 
being studied. Upon completion of these constructs, we will be able to test the chimeras using 
SRE-luciferase assays. We expect to see increased levels of activity in SRE-luciferase assays 
under low levels of inhibitor applied to the CNFY1 construct as compared to CNFY wild-type 
protein. Variable levels of inhibitors in the assay will allow us to reproduce the results described 
in the previous study [19], and to explore the functionality of chimeric constructs.  
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